A drug target is considered "novel" if it represents a new approach to treating cancer, either by targeting a previously unrecognized molecule or pathway or by offering a new mechanism of action. Novelty can also come from the application of existing knowledge in a new way, such as combining therapies to enhance efficacy or reduce resistance.
